clinical trial · NCT06858397
A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
Fabry DisesaseHM15421/GC1134A
brief summary
This Phase 1/2 first-in-human (FIH) study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15421 in patients with FD.
started
May 14, 2025
primary completion
Aug 30, 2028
completion
Aug 30, 2028
last updated
Nov 4, 2025
official title
An Open Label, Dose Range, Proof-of-Concept Study to Assess the Safety and Efficacy of HM15421/GC1134A in Patients With Fabry Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol